[EN] COMBINATION OF CB2 MODULATORS AND PDE4 INHIBITORS FOR USE IN MEDICINE<br/>[FR] COMBINAISON DE MODULATEURS DU CB2 ET D'INHIBITEURS DE LA PDE4 UTILISEE EN MEDECINE
申请人:GLAXO GROUP LTD
公开号:WO2005074939A1
公开(公告)日:2005-08-18
Combination of one or more CB2 modulators such as a compound of formula (I), (II) and (III); and one more PDE4 inhibitors are useful of treating conditions which are mediated by the activity of CB2 receptors or conditions which are mediated by PDE4, such as an immune disorder, an inflamatory disorder, pain, rheumatoid.
[EN] PYRIDINE DERIVATIVES AS CB2 RECEPTOR MODULATORS<br/>[FR] DERIVES DE PYRIDINE EN TANT QUE MODULATEURS DU RECEPTEUR CB2
申请人:GLAXO GROUP LTD
公开号:WO2004029027A1
公开(公告)日:2004-04-08
The present invention relates to novel pyridine derivatives of formula (I) pharmaceutical compositions containing these compounds and their use in the treatment of diseases, particularly pain, which diseases are caused directly or indirectly by an increase or decrease in activity of the cannabinoid receptor.
[EN] PYRIMIDINE DERIVATIVES AS CANNABINOID RECEPTOR MODULATORS<br/>[FR] DERIVES DE PYRIMIDINE UTILISES COMME MODULATEURS DES RECEPTEURS CANNABINOIDES
申请人:GLAXO GROUP LTD
公开号:WO2005080350A1
公开(公告)日:2005-09-01
The present invention relates to novel pyrimidine derivatives such as compounds of the formula (I) and the use of such compounds or pharmaceutical compositions thereof in the treatment of diseases, particularly pain, which are mediated by the activity of the cannabinoid 2 receptor.
[EN] PYRIMIDINE COMPOUNDS<br/>[FR] COMPOSES DE PYRIMIDINE
申请人:GLAXO GROUP LTD
公开号:WO2004018434A1
公开(公告)日:2004-03-04
The present invention relates to novel pyrimidine derivatives, pharmaceutical compositions containing these compounds and their use in the treatment of diseases, particularly pain, which diseases are caused directly or indirectly by an increase or decrease in activity of the cannabinoid receptor.
The present invention relates to novel pyrimidine derivatives, pharmaceutical compositions containing these compounds and their use in the treatment of diseases, particularly pain, which diseases are caused directly or indirectly by an increase or decrease in activity of the cannabinoid receptor.